“Multi-Chem is no longer a manufacturing transition story. It is a mature regional cybersecurity and network-performance distributor, with residual printed circuit board exposure immaterial to the investment case,” says Eng Tiam Choon of uSmart Research Institute. “The key test is whether M.Tech can sustain margins, cash generation and channel relevance across its regional vendor-reseller ecosystem,” he adds.
Eng describes M.Tech as a value-added distributor (VAD) of cybersecurity and network performance solutions, working with global technology vendors and reaching customers primarily through reseller partners, including system integrators that serve end users such as financial institutions and government bodies. Besides distributing products, M.Tech works with technology vendors and reseller partners, providing technical support, maintenance and professional services, such as on-site deployment and software upgrades and certified training.
Big names in vendor portfolio
“This VAD model strengthens M.Tech’s channel relevance and supports stickiness in the vendor-reseller ecosystem, distinguishing it from a basic pass-through distribution model,” says Eng. M.Tech’s disclosed vendor portfolio includes several recognised cybersecurity and network-performance names, including Check Point, Cisco, CyberArk, Darktrace and Trend Micro.
The company is very closely held and managed by the Foo family. As at March 16, CEO Foo Suan Sai, who founded the company some four decades ago, and his wife Han Juat Hoon, the chief operating officer, collectively own 68.35% of Multi-chem through direct and deemed interests. Their son, Foo Fang Yong, is also on the board as an executive director and serves as the company’s general manager. From Eng’s perspective, this reflects strong economic alignment with shareholders but also meaningful concentration of control.
See also: With no ‘sell in May’, SGX enjoys higher target prices on ‘strong’ May
Founder-led and family-controlled companies such as Multi-Chem support management-shareholder alignment given the founders’ substantial economic interest. Still, control is also concentrated in the family and limits minority-shareholder influence, says Eng.
Nonetheless, Eng has condensed his investment view for Multi-Chem into three pillars. First, the company’s specialist cybersecurity VAD platform is underappreciated. He calls out the “outdated” view that Multi-Chem is still a legacy player in the printed circuit board industry. Rather, the IT distribution business already accounted for nearly all revenue, with the PCB portion in FY2025 an “immaterial” $0.4 million.
“M.Tech should be assessed as a regional cybersecurity and network-performance VAD ... a relevant platform in the vendor-distributor-reseller channel where products require technical support, reseller enablement and implementation capability,” says Eng.
See also: DBS lays out case for DFI Retail to move ahead with Hong Kong supermarket consolidation
Next, the company saw lower earnings in FY2025, but that weakness, from Eng’s perspective, is “recoverable”. He points out that the weaker numbers were due to softer IT sales, US dollar depreciation against the Singapore dollar and elevated inventory-related charges and that gross margin dipped to 13.7% from the stable range of 14.1%–14.4% between FY2021 and FY2024. “The weakness is attributable to cyclical factors rather than structural margin deterioration,” says Eng, who expects gross margin to normalise to 14.1% in FY2026–FY2027, thereby supporting earnings recovery from $26.4 million in FY2026 to $30.4 million in the following FY2027.
Net cash with zero bank borrowings
Lastly, the company is in net cash and the valuation should be further supported with dividends. The company ended FY2025 with $98.1 million in net cash, zero bank borrowings, and a “meaningful” equity-value buffer. Based on an 85% payout ratio, Eng is forecasting a dividend per share of 28.66 cents for FY2026 and 30.22 cents for FY2027. “The key monitoring point is working capital — if revenue recovery requires heavier inventory rebuild or customer credit extension, free cash flow and dividend cover could tighten,” says Eng.
Eng’s target price for Multi-Chem is $4.79, based on a blended framework comprising 80% discounted cash flow, 10% EV/Revenue, and 10% EV/Ebitda. According to Eng, discounted cash flow remains the primary valuation anchor, as Multi-Chem’s equity value is driven mainly by its own cash-flow recovery, sizeable net cash position, low financial leverage and working-capital discipline. Relative valuation is retained as a secondary market cross-check, given the absence of a direct listed cybersecurity and network-performance VAD peer.
